Amlodipine/olmesartan/rosuvastatin - Daewoong Pharmaceutical

Drug Profile

Amlodipine/olmesartan/rosuvastatin - Daewoong Pharmaceutical

Alternative Names: Amlodipine besylate/olmersartan medoxomil/rosuvastatin calcium; Olmersartan medoxomil/amlodipine besilate/rosuvastatin calcium; Olmersartan medoxomil/amlodipine besylate/rosuvastatin calcium; Olmesartan/amlodipine/rosuvastatin

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Daewoong Pharmaceutical
  • Class
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hyperlipidaemia; Hypertension

Most Recent Events

  • 09 Feb 2017 Chemical structure information added
  • 01 Nov 2016 Phase-III clinical trials in Hyperlipidaemia in South Korea (PO) (NCT03009487)
  • 01 Nov 2016 Phase-III clinical trials in Hypertension in South Korea (PO) (NCT03009487)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top